MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Ouro Medicines
Organization & Developments: Ouro Medicines
Parents
Ouro Medicines
Children
*Licensed a bispecific TCE, now called OM336, from Chinese biotech Keymed Biosciences.
*Ouro is in T cell engager (TCE) space with the goal of harnessing T cells to reset the immune systems of patients with chronic immune diseases.
2025: GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset
2025: Series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK
Jumps
Finance & Acquisition: Ouro Medicines
Key People: Ouro Medicines